Given a passage with a question and an answer to that question, classify if the answer actually answers the question into 'yes' or 'no'. Output 'yes' if the answer answers the question and output 'no' if the answer does not answer the question.
--------
Question: Question: Does alirocumab , a Therapeutic Human Antibody to PCSK9 , Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes?
Answer: These results suggest that inhibition of PCSK9 with alirocumab has no effect on CD81 and does not result in increased susceptibility to HCV entry.

Answer: no


Question: Question: Is microvasculopathy observed in early or late endomyocardial biopsies related to angiographically confirmed transplanted heart coronary vasculopathy?
Answer: Microvasculopathy observed early or late after OHT was not related to angiographically confirmed CAV.

Answer: no


Question: Question: Is [ Bevacizumab toxic to human anterior- and posterior-segment cultured cells ]?
Answer: In this study, a 10-fold concentration (compared with common clinical use) of the VEGF-blocking antibody bevacizumab had toxic effects on primary RPE. There was no toxicity for lower concentrations or toxicity to other cell types of the anterior and posterior segments. Therefore, the clinical use of bevacizumab at concentrations of 1-1.25 mg intravitreally seems to be safe.

Answer:
no